PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-9.93%
Negative revenue growth while MRVL stands at 4.29%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-29.32%
Negative gross profit growth while MRVL is at 3.82%. Joel Greenblatt would examine cost competitiveness or demand decline.
89.00%
EBIT growth above 1.5x MRVL's 8.09%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
89.00%
Operating income growth above 1.5x MRVL's 15.99%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
103.86%
Positive net income growth while MRVL is negative. John Neff might see a big relative performance advantage.
105.56%
Positive EPS growth while MRVL is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
105.56%
Positive diluted EPS growth while MRVL is negative. John Neff might view this as a strong relative advantage in controlling dilution.
0.07%
Slight or no buybacks while MRVL is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
0.33%
Diluted share reduction more than 1.5x MRVL's 1.17%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
-3.01%
Both companies cut dividends. Martin Whitman would look for a common factor, such as cyclical downturn or liquidity constraints.
-109.49%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-487.33%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
20.18%
10Y revenue/share CAGR under 50% of MRVL's 56.20%. Michael Burry would suspect a lasting competitive disadvantage.
8.64%
5Y revenue/share CAGR under 50% of MRVL's 109.65%. Michael Burry would suspect a significant competitive gap or product weakness.
-27.24%
Negative 3Y CAGR while MRVL stands at 25.49%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
No Data
No Data available this quarter, please select a different quarter.
-140.49%
Negative 5Y OCF/share CAGR while MRVL is at 45.44%. Joel Greenblatt would question the firm’s operational model or cost structure.
-118.39%
Negative 3Y OCF/share CAGR while MRVL stands at 63.72%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-89.63%
Negative 10Y net income/share CAGR while MRVL is at 653.69%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-87.29%
Negative 5Y net income/share CAGR while MRVL is 220.76%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-95.45%
Negative 3Y CAGR while MRVL is 202.86%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
No Data
No Data available this quarter, please select a different quarter.
176.77%
5Y equity/share CAGR above 1.5x MRVL's 19.67%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
73.88%
Positive short-term equity growth while MRVL is negative. John Neff sees a strong advantage in near-term net worth buildup.
88.03%
10Y dividend/share CAGR above 1.5x MRVL's 0.04%. David Dodd checks if the firm's robust cash flows justify outpacing the competitor's increases.
40.38%
Stable or rising mid-term dividends while MRVL is cutting. John Neff sees an edge in consistent payouts vs. the competitor.
36.61%
Our short-term dividend growth is positive while MRVL cut theirs. John Neff views it as a comparative advantage in shareholder returns.
-2.29%
Firm’s AR is declining while MRVL shows 11.24%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
4.58%
Inventory growth well above MRVL's 4.05%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
-4.42%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
0.99%
Positive BV/share change while MRVL is negative. John Neff sees a clear edge over a competitor losing equity.
-3.24%
We’re deleveraging while MRVL stands at 3.89%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-55.74%
Our R&D shrinks while MRVL invests at 1.74%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-10.57%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.